Navigation Links
Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo

PAION AG and US Partner Forest Laboratories, Inc. Today Announced the Top Line Results of the DIAS-2 (Desmoteplase In Acute Ischemic Stroke) Study with the Compound Desmoteplase

Aachen (Germany), May 31st, 2007 - PAION AG (Frankfurt Stock Exchange, Prime Standard: PA8) and its US partner Forest Laboratories, Inc. (NYSE: FRX) today announced topline results of the DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with the compound Desmoteplase. The Phase III study was designed to investigate the improvement of clinical outcome in patients with acute ischemic stroke treated with Desmoteplase within 3 to 9 hours after onset of stroke symptoms as compared to placebo. The primary efficacy endpoint (difference between active treatment and placebo in percentage of composite responders as defined below) was not met. The blinded, randomized, placebo-controlled, dose-ranging trial was jointly conducted by PAION and Forest Laboratories, Inc., and enrolled a total of 186 patients in Europe, USA, Canada, Australia, Hong Kong and Singapore. Forest Laboratories, Inc., is the partner of PAION for Desmoteplase for North America and H. Lundbeck A/S for the rest of the world.

In this study, patients received either placebo (N=63), 90 mcg/kg (N=57), or 125 mcg/kg (N=66) of Desmoteplase as an intravenous bolus within 3-9 hours after the onset of stroke. Patients were eligible for treatment only in case of a distinct penumbra of at least 20% (insufficiently perfused but still salvageable tissue area around the primary location of stroke), which was confirmed by magnetic resonance imaging (MRI) or perfusion computed tomography (pCT). The primary efficacy endpoint in the study was clinical improvement at Day 90 defined for each patient as achievement of all three of the following criteria; (1): Improvement of greater than or equal to 8 points from baseline on the National Institutes of Health Stroke Scale (NIHSS) or N
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:6/19/2013)... CLARA, Calif. , June 19, 2013 /PRNewswire/ ... control solutions for life sciences process applications, announced ... glass bioreactors for upstream cell culture and fermentation.  ... a new product family of Finesse bioreactors and ... and cGMP applications.  They are fully compatible with ...
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a ... BDX ), a leading global medical technology company, today announced ... , the latest in its line of high-performance research flow ... delivers high-performance multicolor analysis with the most compact footprint in ... cm) and a height of 30" (76.2 cm). Recognizing that ...
Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
(Date:6/20/2013)... 20, 2013 In an article found ... recently, that can show similarities between an addiction to ... explain the current global obesity pandemic. , To test ... just as one can be addicted to drugs, Dr ... Science at the University of Guelph, has studied the ...
(Date:6/20/2013)... (PRWEB) June 20, 2013 Creighton ... Education Community Service Honor Roll – the highest federal ... commitment to volunteering, student- service learning and civic engagement ... presented by the Corporation for National and Community Service, ... sixth for Creighton. “Our foundation at Creighton is based ...
(Date:6/19/2013)... 20, 2013 Everyone is looking for ways to ... way to do so. It is called Skin Brushing . ... 5 minutes per day - to improve health and skin quality. ... health. How? , Skin Brushing improves general health because:, ... aids the lymphatic system to drain toxins , it ...
(Date:6/19/2013)... 20, 2013 Shreya Rangarajan of Roland ... youth summit on the future of medicine. , ... Global Youth Summit on the Future of Medicine and ... School and the state of Maryland at the Summit. ... practice in an environment hard to imagine just a ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 A man returning from ... he used to be. In his debut book titled RED DANCER ... veteran who immerses himself back home, looking for the right place ... De Los Angeles, former marine from the Vietnam War, returns to ... the edge off his PTSD. Wings, a wealthy acquaintance from a ...
Breaking Medicine News(10 mins):Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2
... Tender Offer Connected with Previously Announced Plans to Separate Medical ... Technology and Funeral Services Businesses, ... ) (the "Company") announced today that it has,commenced a cash ... percent Senior Notes due 2009 (CUSIP No. 431573AD6), of which ...
... 29 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... its fourth quarter and full year 2007 financial,results on ... and is,hosting a conference call and webcast to discuss ... Management will discuss financial results for the,fourth quarter and ...
... With the State of,Minnesota facing a $935 million ... to ensure that the health and independence of,the ... "On the one hand, legislators are discussing meaningful ... chronic conditions, and on the,other, we expect the ...
... The Board of,Directors of Schering-Plough Corporation (NYSE: ... for Ian McInnes, Ph.D., to senior vice,president and ... vice,president, Global Supply Chain. The change reflects the ... that now includes operations from,Organon BioSciences N.V., acquired ...
... the disease , , FRIDAY, Feb. 29 (HealthDay News) -- While ... also play a major role in the development of the ... on more than 40,000 twins born in 1958 or earlier, ... risk for chronic bronchitis and that 14 percent of the ...
... Feb. 29 The American people,through the ... and,a consortium of four partners, will assist ... implement HIV/AIDS prevention, malaria and child,survival programs. ... project,will involve district stakeholders, the private sector ...
Cached Medicine News:Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:USAID Implements Behavior Change and Social Marketing Program in Rwanda 2
... LASIK Marker Has Two ... Evenly Distributed Marks, Providing ... Lamellar Flap To Insure ... Marks Prevent Inadvertent Placement ...
... Be Used With The Gills Nomograms. 6mm ... Cornea For Making Limbal Relaxing Incisions., , 8-12108-5 ... Nomograms. 6mm & 8mm Chord Length Radials Placed ... Inner Circle Assists In Sizing A Precise Capsulorrhexis ...
... Manually Dilate A Small Pupil With Greater ... Safety By Allowing The Iris Hooks To ... The Plane Of The Anterior Capsule, Thus ... Pupil Stretching Is Also Maximized, With The ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture., ... Providing Unobstructed Around-The-Clock Access To The ...
Medicine Products: